High-amylose sodium carboxymethyl starch matrices for oral, sustained drug-release:: Formulation aspects and in vitro drug-release evaluation

被引:22
作者
Brouillet, F. [1 ,2 ]
Bataille, B. [2 ]
Cartilier, L. [1 ]
机构
[1] Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada
[2] Univ Montpellier 1, CIRAD, UMR 016, Fac Pharm, Montpellier, France
关键词
drug delivery; sustained release; excipient; polymer; tablet; matrix; starch; amylose; in vitro;
D O I
10.1016/j.ijpharm.2007.12.039
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
High-amylose sodium carboxymethyl starch (HASCA), produced by spray-drying (SD), was previously shown to have interesting properties as a promising pharmaceutical sustained drug-release tablet excipient for direct compression, including ease of manufacture and high crushing strength. This study describes the effects of some important formulation parameters, such as compression force (CF), tablet weight (TW), drug-loading and electrolyte particle size, on acetaminophen-release performances from sustained drug-release matrix tablets based on HASCA. An interesting linear relationship between TW and release time was observed for a typical formulation of the system consisting of 40% (w/w) acetaminophen as model drug and 27.5% NaCl as model electrolyte dry-mixed with HASCA. Application of the Peppas and Sahlin model gave a better understanding of the mechanisms involved in drug-release from the HASCA matrix system, which is mainly controlled by surface gel layer formation. Indeed, augmenting TW increased the contribution of the diffusion mechanism. CFs ranging from 1 to 2.5 tonnes/cm(2) had no significant influence on the release properties of tablets weighing 400 or 600 mg. NaCl particle size did not affect the acetaminophen-release profile. Finally, these results prove that the new SD process developed for HASCA manufacture is suitable for obtaining similar-quality HASCA in terms of release and compression performances. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:52 / 60
页数:9
相关论文
共 16 条
[1]  
BILARIEDIS CG, 1991, CAN J PHYSL PHARM, V69, P60
[2]   Substituted amylose as a matrix for sustained drug release [J].
Chebli, C ;
Moussa, I ;
Buczkowski, S ;
Cartilier, L .
PHARMACEUTICAL RESEARCH, 1999, 16 (09) :1436-1440
[3]   Effect of some physical parameters on the sustained drug-release properties of substituted amylose matrices [J].
Chebli, C ;
Cartilier, L .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 193 (02) :167-173
[4]  
FORD JL, 1987, INT J PHARM, V40, P233
[5]  
INGANI H, 1986, P 4 INT C PHARM TECH, P272
[6]  
LEVINA M, 2004, DRUG DELIV TECHN JAN, V4
[7]   Substituted amylose matrices for oral drug delivery [J].
Moghadam, S. H. ;
Wang, H. W. ;
El-Leithy, E. Saddar ;
Chebli, C. ;
Cartilier, L. .
BIOMEDICAL MATERIALS, 2007, 2 (01) :S71-S77
[8]   High-amylose carboxymethyl starch matrices for oral sustained drug-release:: In vitro and in vivo evaluation [J].
Nabais, T. ;
Brouillet, F. ;
Kyriacos, S. ;
Mroueh, M. ;
da Silva, P. Amores ;
Bataille, B. ;
Chebli, C. ;
Cartilier, L. .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2007, 65 (03) :371-378
[9]   A SIMPLE EQUATION FOR THE DESCRIPTION OF SOLUTE RELEASE .3. COUPLING OF DIFFUSION AND RELAXATION [J].
PEPPAS, NA ;
SAHLIN, JJ .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1989, 57 (02) :169-172
[10]  
PEPPAS NA, 1985, PHARM ACTA HELV, V60, P110